

Private Hospital National Expenditures

2003-2004

Highly Specialized Drugs Program



Acromegaly

Treatment of excessive growth hormones

Lanreotide

Code 6332G

Data	Qtr1	Qtr2	Qtr3	Qtr4	Grand Total
Dispensed Quantity	n/a	n/a	23	n/a	23
Script Numbers	n/a	n/a	9	n/a	9
Total Cost	n/a	n/a	\$17,982	n/a	\$17,982

Lanreotide Acetate Code 6332G

Data	Qtr1	Qtr2	Qtr3	Qtr4	Grand Total
Dispensed Quantity	27	36	9	15	87
Script Number	14	18	4	8	44
Total Cost	\$21,125	\$28,164	\$7,039	\$11,737	\$68,065

Octerotide

Code 6227R


Data	Qtr1	Qtr2	Qtr3	Qtr4	Grand Total
Dispensed Quantity	1,480	480	1,250	420	3,630
Script Number	18	9	15	8	50
Total Cost	\$13,628	\$4,435	\$11,510	\$3,881	\$33,454

OCTREOTIDE ACETATE Code 6267W

Data	Qtr1	Qtr2	Qtr3	Qtr4	Grand Total
Dispensed Quantity	31	33	13	18	95
Script Number	29	30	13	15	87
Total Cost	\$44,949	\$47,845	\$18,853	\$26,091	\$137,738

Conclusion on Acromegaly

Any Questions?



Octreotide Acetate
\$137,738

Lanreotide Acetate
\$68,065

Octreotide
\$33,454

Lanreotide
\$17,982